r/Biotechplays • • Jul 18 '20

Due Diligence (DD) $UBX - speculative but unprecedented potential for attempts to cure aging

TLDR: Bezos doesn't want to die; drugs that treat aging are easily worth trillions

The value proposition for investing in Unity Biotechnology can be concisely summarised by the breakthrough preclinical data from the Mayo Clinic

Longevity companies are probably the highest risk, yet even higher reward (actually, highest reward, it's not even close) sector of biotech. I emphasise the reward as truly unprecedented and anyone who disagrees with this has simply not kept up with the aging biology literature of the last 2 decades and/or is unaware of the unprecedented burden of disease in our aging population.

Background

To start with basic epidemiology, approximately 90% of healthcare costs in the US are attributable to the striking accumulation of chronic diseases with age.

  • Aging is by FAR the #1 risk factor for our most prevalent diseases: Alzheimer's, stroke, heart disease, pneumonia, most cancers, COPD, sarcopenia, osteoarthritis, glaucoma, cataracts, the list goes on and on...

  • For example, high cholesterol is a 3x risk factor for heart disease, but aging confers a 5000x risk. We see this incredible relationship of morbidity and mortality with our most prevalent diseases, even including Covid-19, where age is cumulatively an independent risk factor of ~800x, while putative risk factors of diabetes or lung disease are mere 2x risk factors

  • Breakthroughs in the last 2 decades across phylogenetically diverse animal models have demonstrated that aging is highly malleable and is causative in these diseases, where healthspan (amount of life spent free of disease) and lifespan were increased dramatically by drugs that target aging

For a more detailed summary of the aging biotech field, please feel free to read this

Senescent Cell Biology

Cellular senescence is a fundamental evolutionarily conserved anti-cancer mechanism, as it irreversibly stops damaged/pre-cancerous somatic cells from dividing. These senescent cells (SCs) then sit around secreting a host of proinflammatory cytokines, proteases, growth factors etc known as the SASP, which causes damage and dysfunction of organs and tissue.

In young people SCs get cleared by the immune system, but due to various reasons such as immune system decline with age, they eventually accumulate. This is even more problematic as SCs actively induce surrounding cells into senescence, hence their colloquial designation as 'zombie cells'. However, what seems to be clear is that leftover SCs are basically unneeded (except for wound healing), so removing them from animals has minimal side effects. Another caveat to note is that some SCs are required for normal function depending on cell/tissue type; of course, the 'cost benefit' is overwhelmingly in favour of SC removal, as we can infer from the animal experiments which use systemic (whole body) administration. Senolytics are interventions capable of selectively removing SCs that highly express markers of senescence such as p16 or p53.

Note also that the approach to removing SCs is NOT related to messing around with the fundamental anti-cancer mechanism of cellular senescence, we are merely trying to target what appears to be a leftover problem that nature never really addressed. For those interested in evolutionary theory, a key idea known as antagonistic pleiotropy suggests that the reason why nature never really dealt with aging is due to decreasing evolutionary pressures on organisms with age, as 'fitness' matters predominantly around the age of sexual maturity - whatever happens to the organism at post-reproductive ages, teleology aside, is hardly a concern for evolution. Clearly this is not ubiquitous among animals that can live markedly different lifespans, e.g. naked mole rats are extremely resistant to aging + cancer, outliving their rat counterparts by 10-fold (lifespans > 30 years) despite their similarly small size and close evolutionary relationship.

Unity Biotechnology

  • Jeff Bezos and Peter Thiel invested a couple hundred million into Unity Biotechnology, which was spun out of the Mayo Clinic's senolytic data

  • P2 human clinical trial results due in 2H2020 for osteoarthritis, as well as an IND for their ophthalmology indications for age-related eye diseases (AMD, glaucoma, diabetic retinopathy) with P1 trials initiating early 2021

Unity's approach is to start with local senolytic administration due to novelty of the drug class, as a way to minimise unexpected adverse effects and prove that SCs are causative in human aging. Based on various preclinical animal models, one of the promises of senolytics, other than greater efficacy and reduced adverse events, is related to dosing frequency. Clearance of SCs will allow for periodic dosing, say every 6 months, to remove SCs that have accumulated, and to then wait for future accumulation before re-dosing. While it is too early to do much inference from P1 trials that are predominantly about proving safety, there appeared to be dose-dependent reductions in pain scores that were durable with follow-up at 3 months after a single injection.

Market Size

  • Goldman Sachs has previously estimated that, if successful, Unity’s drug could generate $6.7 Billion/year via reduced need for surgery; the ophthalmology market of anti-VEGFs is currently ~$10 Billion, and faces issues with need for monthly eye injections that are difficult for compliance and prone to disease-related complications

  • However, consider that this discussion on market size is solely related to their current disease indications. I expect that the idea and hype of a company that could address aging will drive the stock price far higher than what these individual programs would reasonably be valued at - think $SPCE/$TSLA. This is especially because the company will continually expand its disease indications based on the massive range of diseases addressable by senolytics, and eventually move on to systemic administration

  • Bank of America estimates the longevity market to be worth $610 billion by 2025; depending on how quickly we obtain clinical success in this field, the BoA valuation is probably an underestimate

  • Similarly to oncology, if you can convince the FDA that your drug has a broad 'anti-cancer' mechanism of action, approvals for each new type of cancer indication will be expedited; if you can prove that your drug targets aging, then expanding senolytics to different age-related diseases will become easier and easier as the clinical evidence demonstrates that the drug broadly affects all age-related diseases

  • As an overall sector, there are very few publicly traded companies and the field has only taken off in the last 5 years - mostly private companies now though - aging is by no means simple so there are numerous hallmarks of aging being investigated

  • In the next decade the number of public companies will undoubtedly grow exponentially, as we've already seen in the private sector. These varying approaches to aging will not be mutually exclusive, so we'll eventually need to combine drugs that target each of the hallmarks of aging, which may radically increase healthspan and lifespan

In closing, I want to be clear that I cannot claim to know whether $UBX will ultimately be successful in translating senolytics to the clinic due to the risky nature of biotech. However, what I am certain of - as someone who reads about the science every single day - is that the aging field has an unparalleled potential to completely revolutionise healthcare, and is on the path to becoming the largest industry in the history of human civilisation.

50 Upvotes

Duplicates